Tag:
Lipitor
Latest Headlines
Latest Headlines
Pfizer, Lilly earnings drop on new generic rivals
Pfizer ( $PFE ) and Eli Lilly ( $LLY ) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earnings
Lipitor brand loses ground as generics take hold
Pfizer ( $PFE ) faces another stumbling block on its Lipitor obstacle course. As The Wall Street Journal reports, Express Scripts ( $ESRX ) is moving the cholesterol drug to a less-favorable spot on its
Experts debate preventive use of statins
No question, the cholesterol-fighting statin drugs have been a powerhouse class for Big Pharma. One of them--Pfizer's ( $PFE ) Lipitor --was the best-selling branded medication of all time, and plenty
Numbers hint that Pfizer's Lipitor strategy may work
The latest figures on Lipitor sales suggest that Pfizer's ( $PFE ) aggressive sales strategies might—just might—be working. As The Associated Press reports, new IMS Health numbers show
Shrinking Pfizer targeting new round of small, tailor-made buyouts and pacts
Pfizer is thinking small these days. In keeping with the deal-making theme at the J.P. Morgan conference, Pfizer ( $PFE ) CEO Ian Read carefully mapped out the pharma giant's near-term strategy, with
UPDATED: Fueled by Sanofi, Warp Drive Bio takes off with $125M deal
Biotech startup Warp Drive Bio has scored $125 million in financing from a syndicate that features the French drug giant Sanofi ( $SNY ) along with founding backer Third Rock Ventures and the VC firm
Pfizer's Lipitor promos won't keep share up, Watson CEO says
Pfizer ( $PFE ) continues to roll out the big guns to protect its Lipitor market share, but at least one rival drugmaker says those efforts won't pay off as well as the company hopes. Watson
Generics slash Pfizer's Lipitor sales
Competition has hit Pfizer's ( $PFE ) blockbuster Lipitor , and hit it hard. Sales of the cholesterol drug dropped by half barely a week after it started facing generic competition in the U.S.,
Watson takes big initial chunk of generic Lipitor sales
The numbers are in. The Wall Street Journal's Health Blog is reporting that generic versions of Lipitor from Watson Pharmaceuticals ( $WPI ) and Ranbaxy Laboratories took roughly 14.6% of prescription
Ranbaxy taps U.S. exec as regulatory watchdog
Last week, Ranbaxy Laboratories surprised many pharma-watchers with an 11th-hour approval for its copycat version of the Pfizer ( $PFE ) blockbuster Lipitor . The company had been promising it would
